Novo Nordisk AS Newswire (Page 7)

Novo Nordisk AS Newswire (Page 7)

Comprehensive Real-Time News Feed for Novo Nordisk AS. (Page 7)

Results 121 - 140 of 5,713 in Novo Nordisk AS

  1. Oct 18, 2017 17:34 EDTNovo Nordisk receives positive 16-0 vote from...Read the original story w/Photo

    Sep 29, 2017 | PR Newswire

    Novo Nordisk today announced that the Endocrinologic and Metabolic Drugs Advisory Committee of the U.S. Food and Drug Administration voted 16-0, supporting the approval of once-weekly semaglutide to improve glycemic control in adults with type 2 diabetes. One member of the committee abstained.

    Comment?

  2. Trial shows drug can dramatically reduce weight of people with obesityRead the original story w/Photo

    Oct 23, 2017 | PhysOrg Weblog

    A drug that targets the appetite control system in the brain could bring about significant weight loss in people with clinical obesity, according to new research. On average, people lost 5kg over a 12 week period after receiving weekly doses of semaglutide, a compound currently being developed as a treatment for Diabetes.

    Comment?

  3. Janus Henderson Group PLC Invests $9.17 Million in Novo Nordisk A/SRead the original story

    Oct 23, 2017 | IntersportsWire

    Janus Henderson Group PLC bought a new position in shares of Novo Nordisk A/S during the second quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor bought 213,790 shares of the company's stock, valued at approximately $9,169,000.

    Comment?

  4. New medicine for obesity hits Qatar marketRead the original story w/Photo

    Oct 22, 2017 | The Peninsula

    A new intravenous medicine is now available in Qatar, which could help overweight or obese people to slim down, and prevent from developing other chronic diseases. Saxenda, a product of Novo Nordisk, is indicated as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adults with obesity or who are overweight with at least one weight-related comorbidity, said experts yesterday.

    Comment?

  5. Novo Nordisk A/S (NVO) Sets New 12-Month High at $50.61Read the original story

    Oct 21, 2017 | The Breeze

    Novo Nordisk A/S shares reached a new 52-week high on Thursday . The stock traded as high as $50.61 and last traded at $50.63, with a volume of 1,848,039 shares traded.

    Comment?

  6. Novo Provides Corporate UpdateRead the original story w/Photo

    Oct 20, 2017 | GlobeNewswire

    Novo Resources Corp. reports the appointment of Messrs. Rob Humphryson and Michael Barrett as directors of the Company, replacing Messrs.

    Comment?

  7. Eli Lilly Looks Over Its Shoulder After Novo Nordisk Wins FDA Panel Backing for Diabetes DrugRead the original story w/Photo

    Oct 18, 2017 | BioSpace

    An advisory panel with the U.S. Food and Drug Administration gave a near unanimous support to Novo Nordisk 's diabetes drug semaglutide, a long-acting GLP-1 analogue. In a 16 to 0 vote that included one abstention, the FDA's Endocrinologic and Metabolic Drugs Advisory Committee supported the potential approval of once-weekly semaglutide to improve glycaemic control in adults with type 2 diabetes.

    Comment?

  8. Novo Nordisk takes aim at Eli Lilly with U.S. backing of new diabetes drugRead the original story w/Photo

    Oct 19, 2017 | Reuters

    FILE PHOTO: The logo of Danish multinational pharmaceutical company Novo Nordisk is pictured on the facade of a production plant in Chartres, north-central France, April 21, 2016. REUTERS/Guillaume Souvant WASHINGTON/COPENHAGEN - Denmark's Novo Nordisk will take aim at Eli Lilly in the growing diabetes market after an advisory panel to the U.S. Food and Drug Administration gave the green light to its semaglutide drug.

    Comment?

  9. Eli Lilly Looks Over Its Shoulder After Novo Wins FDA Panel Backing for Diabetes DrugRead the original story w/Photo

    Oct 18, 2017 | BioSpace

    One member of the committee abstained. Based on the data included in the New Drug Application for semaglutide, the FDA asked the panel members to discuss whether Novo Nordisk has provided adequate evidence to establish the efficacy and safety profile of semaglutide for the treatment of type 2 diabetes in adults.

    Comment?

  10. U.S. FDA panel backs approval of Novo Nordisk diabetes drugRead the original story w/Photo

    Oct 18, 2017 | Reuters

    Novo Nordisk A/S's new diabetes drug semaglutide is effective, reasonably safe and should be approved, an advisory panel to the U.S. Food and Drug Administration concluded on Wednesday. The panel voted 16-0 with one abstention in favor of the drug being approved.

    Comment?

  11. podcast - episode 77: What's up with the Witwatersrand?Read the original story w/Photo

    Oct 18, 2017 | The Northern Miner

    This week we've got a geological bonananza! Lesley sits down with Dr. Hartwig Frimmel to chat about the genesis of the Witwatersrand gold deposit in South Africa. The geological anomaly has received renewed attention thanks to a recent discovery by Novo Resources , which reported on July 12 that it had found gold nuggets up to 4 cm long during trenching at its Purdy's Reward gold prospect in Western Australia.

    Comment?

  12. Novo Nordisk Receives Positive 16-0 vote from FDA Advisory Committee...Read the original story w/Photo

    Oct 18, 2017 | Drugs.com

    Novo Nordisk today announced that the Endocrinologic and Metabolic Drugs Advisory Committee of the U.S. Food and Drug Administration voted 16-0, supporting the approval of once-weekly semaglutide to improve glycemic control in adults with type 2 diabetes. One member of the committee abstained.

    Comment?

  13. Hunger-blocking injection lets fat monkeys quickly lose weightRead the original story w/Photo

    Oct 18, 2017 | New Scientist

    Excitement is growing about a protein called GDF15, which naturally regulates body weight in humans and animals. When extra amounts are injected into mice, they eat less, lose weight and have fewer signs of diabetes .

    Comment?

  14. Pricking your fingers may someday be a thing of the past for...Read the original story w/Photo

    Oct 18, 2017 | News 88.9 KNPR

    For people with diabetes, keeping blood sugar levels in a normal range - not too high or too low - is a lifelong challenge . New technologies to ease the burden are emerging rapidly, but insurance reimbursement challenges, supply shortages, and shifting competition make it tough for patients to access them quickly.

    Comment?

  15. Diabetes Technology Moves Closer To Making Life Easier For PatientsRead the original story w/Photo

    Oct 18, 2017 | New Hampshire Public Radio -

    For people with diabetes, keeping blood sugar levels in a normal range - not too high or too low - is a lifelong challenge . New technologies to ease the burden are emerging rapidly, but insurance reimbursement challenges, supply shortages, and shifting competition make it tough for patients to access them quickly.

    Comment?

  16. Eagles 40-Day Challenge: Rrainers share workouts to help fans fit in fitnessRead the original story w/Photo

    Oct 17, 2017 | Philly.com

    The birds along with Rothman Institute at Jefferson and Novo Nordisk, started the platform to get fans up off their feet and eating healthy foods. The challenge is free and encourages participants to drink eight glasses of water, catch eight hours of sleep and complete 20 minutes of physical activity.

    Comment?

  17. Core Drilling Supports Strong Continuity of Conglomerates at Purdy's RewardRead the original story w/Photo

    Oct 17, 2017 | GlobeNewswire

    Plan map showing completed and planned diamond core drilling at the Purdy's Reward prospect. The location of two cross sections shown in Figure 2 is also provided.

    Comment?

  18. Verition Fund Management LLC Takes $670,000 Position in Novo Nordisk A/SRead the original story

    Oct 17, 2017 | IntersportsWire

    Verition Fund Management LLC purchased a new position in shares of Novo Nordisk A/S during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor purchased 15,616 shares of the company's stock, valued at approximately $670,000.

    Comment?

  19. Is Novo Nordisk Still A Buy?Read the original story w/Photo

    Oct 16, 2017 | Seeking Alpha

    Big Pharma was the first sector I analyzed with the view to producing an article for Seeking Alpha. Out of that analysis came a buy recommendation for Novo Nordisk .

    Comment?

  20. Novo Nordisk diabetes drug works; no heart risk-FDA reviewRead the original story w/Photo

    Oct 16, 2017 | Reuters

    Novo Nordisk A/S's closely watched diabetes drug semaglutide is effective, caused no heart risk, and carried only limited risk of sight problems, a preliminary review by the U.S. Food and Drug Administration concluded on Monday, sending the company's shares up 4 percent. The review, posted on the FDA's website, comes two days ahead of a meeting of advisors to the agency who will discuss the drug, semaglutide, and recommend whether it should be approved.

    Comment?